Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.

Morlán-Coarasa MJ, Arias-Loste MT, Ortiz-García de la Foz V, Martínez-García O, Alonso-Martín C, Crespo J, Romero-Gómez M, Fábrega E, Crespo-Facorro B.

Psychopharmacology (Berl). 2016 Sep 12. [Epub ahead of print]

PMID:
27620899
2.

Induced next-day somnolence in an elderly patient taking suvorexant concomitantly with diltiazem.

Shihyakugari A, Hori S, Miki A, Sawada Y.

Int J Clin Pharmacol Ther. 2016 Aug;54(8):645-8. doi: 10.5414/CP202624.

PMID:
27191770
3.

Medical Approach to the Management of Traumatized Refugees.

Kinzie JD.

J Psychiatr Pract. 2016 Mar;22(2):76-83. doi: 10.1097/PRA.0000000000000135.

PMID:
27138076
4.

Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches.

Coplan JD, Aaronson CJ, Panthangi V, Kim Y.

World J Psychiatry. 2015 Dec 22;5(4):366-78. doi: 10.5498/wjp.v5.i4.366. eCollection 2015 Dec 22. Review.

5.

Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis.

Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU.

World Psychiatry. 2015 Oct;14(3):339-47. doi: 10.1002/wps.20252.

6.

The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: a focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization.

Nasrallah HA, Harvey PD, Casey D, Csoboth CT, Hudson JI, Julian L, Lentz E, Nuechterlein KH, Perkins DO, Kotowsky N, Skale TG, Snowden LR, Tandon R, Tek C, Velligan D, Vinogradov S, O'Gorman C.

Schizophr Res. 2015 Aug;166(1-3):69-79. doi: 10.1016/j.schres.2015.04.031. Epub 2015 May 28.

PMID:
26027848
7.

Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada.

Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M.

J Med Econ. 2014 Apr;17(4):296-304. doi: 10.3111/13696998.2014.897627. Epub 2014 Mar 11.

PMID:
24564402
8.

[Antipsychotic Treatment of the Adult Patient in the Acute Phase of Schizophrenia].

Bohórquez Peñaranda A, Gómez Restrepo C, García Valencia J, Jaramillo González LE, de la Hoz AM, Arenas Á, Tamayo Martínez N.

Rev Colomb Psiquiatr. 2014;44 Suppl 1:13-28. doi: 10.1016/j.rcp.2015.05.003. Epub 2015 Jul 4. Spanish.

PMID:
26576459
9.

The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics.

Ko YK, Soh MA, Kang SH, Lee JI.

Clin Psychopharmacol Neurosci. 2013 Aug;11(2):80-8. doi: 10.9758/cpn.2013.11.2.80. Epub 2013 Aug 26.

10.

Worsened hypertension control induced by aripiprazole.

Yasui-Furukori N, Fujii A.

Neuropsychiatr Dis Treat. 2013;9:505-7. doi: 10.2147/NDT.S43950. Epub 2013 Apr 15.

11.

Torsades de pointes after administration of low-dose aripiprazole.

Nelson S, Leung JG.

Ann Pharmacother. 2013 Feb;47(2):e11. doi: 10.1345/aph.1R387. Epub 2013 Jan 29.

PMID:
23362038
12.

Prescription of second-generation antipsychotics: responding to treatment risk in real-world practice.

Hermes ED, Sernyak MJ, Rosenheck RA.

Psychiatr Serv. 2013 Mar 1;64(3):238-44. doi: 10.1176/appi.ps.201200183.

PMID:
23241613
13.

Delusional infestation in a patient with renal failure, metabolic syndrome, and chronic cerebrovascular disease treated with aripiprazole: a case report.

Carpiniello B, Pinna F, Tuveri R.

Case Rep Med. 2011;2011:103652. doi: 10.1155/2011/103652. Epub 2011 Nov 17.

14.

A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder.

McIntyre RS, McElroy SL, Eudicone JM, Forbes RA, Carlson BX, Baker RA.

Prim Care Companion CNS Disord. 2011;13(6). pii: PCC.11m01182. doi: 10.4088/PCC.11m01182.

15.

Aripiprazole augmentation induced hypertension in major depressive disorder: a case report.

Hsiao YL, Chen SJ, Shen TW, Chang CH, Chen ST.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):305-6. doi: 10.1016/j.pnpbp.2010.11.024. Epub 2010 Nov 24. No abstract available.

PMID:
21111018
16.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. French.

PMID:
20620267
17.

Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.

Nielsen J, Skadhede S, Correll CU.

Neuropsychopharmacology. 2010 Aug;35(9):1997-2004. doi: 10.1038/npp.2010.78. Epub 2010 Jun 2.

18.

Aripiprazole, hypertension, and confusion.

Pitchot W, Ansseau M.

J Neuropsychiatry Clin Neurosci. 2010 Winter;22(1):123.E33. doi: 10.1176/appi.neuropsych.22.1.123-t.e33. No abstract available.

PMID:
20160240
19.

Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE.

CNS Drugs. 2009 Dec;23(12):1003-21. doi: 10.2165/11530020-000000000-00000. Review.

PMID:
19958039
20.

Aripiprazole and hypertension in adolescents.

Bat-Pitault F, Delorme R.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):601-2. doi: 10.1089/cap.2009.0044. No abstract available.

PMID:
19877990
Items per page

Supplemental Content

Loading ...
Write to the Help Desk